Big Pharma’s Record Spending On Lobbying Won’t Slow Bipartisan Momentum On Drug Prices

Filings Show Drug Makers Spent Nearly $10 Million on Lobbying in Q1 2019 – Up 30 Percent from Q1 2018

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement in response to new filings indicating pharmaceutical companies spent a near-record $9.91 million in lobbying during the first quarter of 2019 – up from $6.03 million in the last quarter of 2018:

“Big Pharma is clearly feeling the heat as policymakers on both sides of the aisle rally behind common-sense, market-based solutions to crack down on the industry’s anti-competitive tactics in order to lower the growing price of prescription drugs,” said CSRxP spokesman Jon Conradi.  “Rather than take responsibility for price-gouging American patients and become part of the solution, Big Pharma is boosting its spending on blame game advertising and lobbying to evade culpability and responsibility.”

“The American people have spoken and demanded Washington act to alleviate the crisis of rising prescription drug prices,” Conradi continued.  “Despite Big Pharma’s millions, we will continue to advocate for progress on bipartisan and market-based solutions, including those espoused by lawmakers on Capitol Hill and the Trump Administration, which will result in lower prices for patients and greater relief for families.”

###